Catheter Ablation Versus Antiarrythmic Drugs for Atrial Fibrillation in China
Information source: Wuhan University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Atrial Fibrillation
Intervention: catheter ablation (Procedure); Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Wuhan University Official(s) and/or principal investigator(s): Cong xin Huang, doctor, Study Chair, Affiliation: Renmin Hospital of Wuhan University
Overall contact: Cong xin Huang, doctor, Phone: 13907131546, Email: huangcongxin@yahoo.com.cn
Summary
The mainstay of treatment for atrial fibrillation remains pharmacological;however,catheter
ablation has increasingly been used over the last decades. The relative merits of each
strategy have not been extensively studied. Our study was designed to determine if catheter
ablation is a feasible option as first-line therapy for treating patients with symptomatic
AF.
Clinical Details
Official title: Atrial Fibrillation Therapy: A Multi-Center Clinical Study
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Number of participants with all-cause deathNumber of participants with all-cause death Number of participants with all-cause death Number of participants with all-cause death severe blooding complications severe blooding complications severe blooding complications severe blooding complications cardio-cerebrovascular complications cardio-cerebrovascular complications cardio-cerebrovascular complications cardio-cerebrovascular complications Number of participants with cardiovascular death events Number of participants with cardiovascular death events Number of participants with cardiovascular death events Number of participants with cardiovascular death events
Secondary outcome: recurrence of atrial arrhythmias (AF, AFL, AT)recurrence of atrial arrhythmias (AF, AFL, AT) recurrence of atrial arrhythmias (AF, AFL, AT) recurrence of atrial arrhythmias (AF, AFL, AT) resource utilization and costs resource utilization and costs resource utilization and costs
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- 1 Patients with symptomatic AF recorded by ECG or Holter 2 Age: 18-75 years 3 Patients
who are willing to enroll in the trial
Exclusion Criteria:
- 1 Patients accompanied hyperthyroidism 2 Patients with sever liver or renal
dysfunction 3 Patients with sever cardiac dysfunction 4 Patients had previous
radiofrequency catheter ablation in the LA or Maze surgical procedure 5 Patients with
emboli in atrium 6 Pregnant woman
Locations and Contacts
Cong xin Huang, doctor, Phone: 13907131546, Email: huangcongxin@yahoo.com.cn
Renmin Hospital of Wuhan University, Wuhan, Hubei, China; Recruiting Cong xin Huang, doctor, Phone: 13907131546, Email: huangcongxin@yahoo.com.cn cong xin Huang, doctor, Principal Investigator
Additional Information
Starting date: April 2011
Last updated: April 21, 2011
|